Ipilimumab for head and neck neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 6 Jul 2016: Trial registered, NCT02823574
  2. 8 Nov 2016: Trial started, NCT02823574

The trials

NCT02823574: Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

State
Completed
Phase
Phase 2
People
425 taking part
Started
8 Nov 2016
Primary completion
23 Jan 2019
Arms
Nivolumab and Ipilimumab
Results
Posted on the registry
  1. 6 Jul 2016: Trial registered
  2. 8 Nov 2016: Trial started
  3. 21 Apr 2022: Trial completed
  4. 21 Apr 2022: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Also known as Yervoy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.